Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILDA: HLI with Azacitidine and Venetoclax in High-Risk AML
NCT04886206Phase 1Unknown
- Sponsor
- CHU de Nantes
- Start
- Nov 2021
- Primary completion
- Nov 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of donor lymphocytes in acute myeloid leukemia (AML), sponsored by CHU de Nantes. Primary endpoint: Dose-Limiting Toxicity at 14 days. Status: unknown.
02
Drugs
donor lymphocytes
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04886206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886206.